FDA has set a Prescription Drug User Fee Act (PDUFA) target action date of February 23, 2027Application supported by positive results from Phase ...

LEO Pharma announces key results of Phase 2 TRAPEDS-1 trial evaluating pharmacokinetics and safety of tralokinumab ...

Arcutis Biotherapeutics said the U.S. Food and Drug Administration has accepted its application seeking expanded approval of its Zoryve topical treatment for infants with atopic dermatitis, the most ...

FDA has set a Prescription Drug User Fee Act (PDUFA) target action date of February 23, 2027Application supported by positive results from Phase 2 open-label INTEGUMENT-INFANT study and Phase 1 open-l ...

Eli Lilly Canada Inc. (Lilly Canada) has officially received a long-awaited positive recommendation (reimbursement with conditions) from Canada's Drug Agency (CDA-AMC) for its medicine, Ebglyss®, for ...

In the INTEGUMENT-INFANT trial, 34.4% of patients achieved vIGA-AD success and 58.3% reached EASI-75 at week 4.

The online team-based connected health (TCH) model yields equivalent improvements in signs and symptoms of atopic dermatitis ...

Watch rot' is trending online, but experts warn smartwatch overuse may cause contact dermatitis. Learn the symptoms, causes ...

These are the blooms to watch out for if you have kids or pets.

Regardless of your hair washing schedule or whether you prefer wash-out masks or leave-in oils, there are lots of scalp ...

Upadacitinib is associated with sustained or improved responses across various patient-reported outcome measures at 140 weeks among those with AD.

He had no idea he was infected with HIV. It progressed to AIDS, and he nearly died before learning the truth.